Technology News and Research

RSS

Bioengineers explain why some neurons die sooner than others in brains of AD patients

Bioengineers from the University of California, San Diego developed an explanation for why some types of neurons die sooner than others in the brains of people with Alzheimer's disease. These insights, published in the journal Nature Biotechnology on November 21, come from detailed models of brain energy metabolism developed in the Department of Bioengineering at the UC San Diego Jacobs School of Engineering.

8 Dec 2010

IEEE members are transforming the future of medicine and healthcare

Members of IEEE, the world's largest technical professional association, are advancing the application of engineering sciences and technology with medicine and biology to make healthcare personal again.

8 Dec 2010

Objet, Clearstep enter collaboration for digital orthodontic solutions

Objet Geometries Ltd., the innovation leader in 3D printing for rapid prototyping and additive manufacturing, today announced collaboration with Clearstep Laboratories, a leading provider of digital orthodontic solutions. Objet's high resolution, 3D printing systems will facilitate Clearstep™ to become more efficient in manufacturing custom-made orthodontic clear aligners on a mass scale. Working together, Clearstep and Objet will bring the advantages of digital printing technology to orthodontics.

8 Dec 2010

Most of world's poorest still live in rural areas, despite progress over last decade, U.N. report says

A report from the U.N.'s International Fund for Agricultural Development found that approximately 350 million people living in rural areas have escaped extreme poverty over the past decade, but most of the world's poorest citizens continue to live in rural regions, the BBC reports (Melik, 12/6).

8 Dec 2010

New technique may help develop novel treatments for brain diseases

Scientists have created a way to isolate neural stem cells - cells that give rise to all the cell types of the brain - from human brain tissue with unprecedented precision, an important step toward developing new treatments for conditions of the nervous system, like Parkinson's and Huntington's diseases and spinal cord injury.

8 Dec 2010

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

Cephalon, Inc. and Mesoblast Limited, today announced they have entered into a strategic alliance to develop and commercialize novel adult Mesenchymal Precursor Stem Cell therapeutics for degenerative conditions of the cardiovascular and central nervous systems.

8 Dec 2010

BioMimetic Therapeutics to assess safety, clinical utility of Augment Rotator Cuff Graft

BioMimetic Therapeutics, Inc. today announced it initiated enrollment in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears. The randomized, controlled pilot trial is expected to include enrollment of up to 30 patients.

8 Dec 2010

AMR begins nationwide initiative to implement Stryker-PRO XT powered stretchers

In an effort to further improve patient care and reduce lifting injuries, American Medical Response has started a nationwide initiative to replace its manual stretchers with state-of-the-art Stryker-PRO XT powered stretchers in every community it serves.

From Stryker 8 Dec 2010

Some in health industry raising concerns about Accountable Care Organizations

CQ HealthBeat: "The medical device industry told the Centers for Medicare and Medicaid Services that it's concerned about whether accountable care organizations could give providers financial incentives to hold back on needed patient care, particularly on technology. Meanwhile, insurance plan executives warned CMS officials that the ACOs could give hospitals and doctors new bargaining leverage in negotiations with insurers.

8 Dec 2010

One Lambda, Luminex renew 10-year human leukocyte antigen technology development partnership

One Lambda Inc., a leading manufacturer and supplier of quality products and technology for the HLA transplant community, and Luminex Corporation have agreed to a long-term renewal of their 10-year strategic partnership aimed at developing platforms and technologies for human leukocyte antigen (HLA).

From Luminex 8 Dec 2010

New sensitive blood test could determine unrecognized heart disease

A more sensitive version of a blood test typically used to confirm that someone is having a heart attack could indicate whether a seemingly healthy, middle-aged person has unrecognized heart disease and an increased risk of dying, UT Southwestern Medical Center researchers have found.

7 Dec 2010

Mobile phones use during pregnancy linked to behavioural problems in kids: Study

A new study finds that pregnant mums who regularly use mobile phones may be more likely to have children with behavioral problems, especially if these kids themselves start using mobile phones in their first seven years.

7 Dec 2010

Miracle Applications to sell and market Bioflex Medical Magnetic products

Miracle Applications Corp. is proud to announce it has entered into a Licensing Agreement with Bioflex Medical Magnetic Inc. to sell and market select Bioflex products. The Bioflex magnet is clinically proven to reduce pain, accelerate healing and improve circulation. Bioflex Medical Magnetic Inc. was formed in October, 1986 and BIOflex® Concentric Circle Magnet is the original magnet for human use.

7 Dec 2010

Fluxion Biosciences announces launch of new BioFlux 1000Z system for live cell imaging

Fluxion Biosciences, Inc. announced that the new BioFlux 1000Z system for live cell imaging will be launched at the 50th American Society for Cell Biology Annual Meeting to be held December 11-15, 2010 in Philadelphia, PA. The BioFlux 1000Z is the latest addition to the BioFlux product family of instruments for cellular analysis under controlled shear flow.

From Fluxion Biosciences 7 Dec 2010

Orthovita granted FDA marketing clearance for Vitoss Bioactive Foam-2X Bone Graft Substitute

Orthovita, Inc. , an orthobiologics and biosurgery company, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Vitoss Bioactive Foam-2X Bone Graft Substitute for use as a non-structural bone void filler for use in the spine, pelvis and extremities. Orthovita expects to launch the newest addition to its bone graft substitute product line by late February or early March of 2011.

7 Dec 2010

Aetna announces agreement to acquire Medicity

Aetna today announced that it has entered into an agreement to acquire Medicity, a health information exchange technology company, headquartered in Salt Lake City, Utah.

7 Dec 2010

FEI launches Magellan extreme resolution scanning electron microscope for life science imaging

FEI Company, a leading instrumentation company providing electron microscope systems for applications in research and industry, today announced the Magellan™ extreme resolution scanning electron microscope (SEM) optimized specifically for life science imaging. The first of its kind, the Magellan SEM enables life science researchers and cell biologists to actually view the entire organization of a cell in its natural, fully-hydrated state.

7 Dec 2010

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark

Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH ("Desitin") were granted approval of the Marketing Authorization Application ("MAA") for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system by the Danish Medicines Agency of Denmark.

7 Dec 2010

Emergent declares one-time cash dividend and regular dividend

Emergent Group Inc., a leading provider of mobile medical lasers and surgical equipment, today announced that the Board of Directors has declared a special, one-time cash dividend of $0.50 per share on its common stock as well as a regular dividend of $0.40 per share, for a total of $0.90 payable December 27, 2010 to shareholders of record December 17, 2010.

7 Dec 2010

Roche completes enrollment in Herceptin SC Phase 3 trial for HER2-positive breast cancer

Halozyme Therapeutics, Inc. today announced that Roche has completed patient enrollment for the pivotal Phase 3 study of Herceptin SC (trastuzumab subcutaneous), a subcutaneous formulation that uses Halozyme's Enhanze™ technology (rHuPH20, recombinant human hyaluronidase).

7 Dec 2010

Technology News and Research

Bioengineers explain why some neurons die sooner than others in brains of AD patients

IEEE members are transforming the future of medicine and healthcare

Objet, Clearstep enter collaboration for digital orthodontic solutions

Most of world's poorest still live in rural areas, despite progress over last decade, U.N. report says

New technique may help develop novel treatments for brain diseases

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

BioMimetic Therapeutics to assess safety, clinical utility of Augment Rotator Cuff Graft

AMR begins nationwide initiative to implement Stryker-PRO XT powered stretchers

Some in health industry raising concerns about Accountable Care Organizations

One Lambda, Luminex renew 10-year human leukocyte antigen technology development partnership

New sensitive blood test could determine unrecognized heart disease

Mobile phones use during pregnancy linked to behavioural problems in kids: Study

Miracle Applications to sell and market Bioflex Medical Magnetic products

Fluxion Biosciences announces launch of new BioFlux 1000Z system for live cell imaging

Orthovita granted FDA marketing clearance for Vitoss Bioactive Foam-2X Bone Graft Substitute

Aetna announces agreement to acquire Medicity

FEI launches Magellan extreme resolution scanning electron microscope for life science imaging

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark

Emergent declares one-time cash dividend and regular dividend

Roche completes enrollment in Herceptin SC Phase 3 trial for HER2-positive breast cancer

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News